Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.

摘要: We conducted a prospective randomized study to compare the results of 3 cycles epidoxorubicin/docetaxel 6 prior surgery in breast cancer patients with clinical stages II and III. Forty-five eligible for neoadjuvant chemotherapy were randomly assigned receive either (group 1) or 2) surgery. Chemotherapy consisted epidoxorubicin 75 mg/m docetaxel on day 1 3-week cycles. The primary endpoint was pathological complete response (pCR) rate; secondary endpoints rates breast-conserving axillary lymph node status both groups. A pCR occurred 10% (two 20) Group 36% (nine 25) 2, which statistically significant (p=0.045). Breast-conserving could be performed 70% (14 76% (19 2 (p=0.065). Axillary negative 45% 52% (13 (p=0.86). conclude that pre-operative versus significantly increases patients.